Related Experiment Videos
New antibiotics for bacterial infections
1University of Pittsburgh School of Medicine, Charles T. Campbell Ophthalmic Microbiology Laboratory, Eye and Ear Institute, University of Pittsburgh, Pittsburgh, PA, USA. mahfs@msx.upmc.edu
Ophthalmology Clinics of North America
|April 10, 2003
Summary
Newer ophthalmic antibiotics like moxifloxacin and gatifloxacin offer potent treatments for bacterial eye infections. Future research in quorum sensing and genomics promises even more advanced antimicrobial agents.
Area of Science:
- Ophthalmology
- Microbiology
- Pharmacology
Background:
- Available ophthalmic antibiotics possess limitations, lacking a universal solution for all bacterial eye infections.
- The ongoing challenge involves developing treatments that are less toxic, cost-effective, require lower dosing frequency, and offer rapid infection clearance.
- Bacterial resistance, adaptability, and rapid reproduction pose significant hurdles in combating infections.
Purpose of the Study:
- To review the evolution and current status of ophthalmic antibiotics.
- To highlight the development of novel antimicrobial agents, including fluoroquinolones.
- To discuss future directions in ophthalmic anti-infective research.
Main Methods:
- Review of existing literature on ophthalmic antibiotics.
- Discussion of the development history of fluoroquinolones.
- Exploration of emerging research areas like quorum sensing and genomics.
Main Results:
- Over 10,000 fluoroquinolone agents have been developed since 1962.
- Newer agents such as moxifloxacin and gatifloxacin represent significant advancements in potency.
- Research into quorum sensing and genomics indicates promising future therapeutic strategies.
Conclusions:
- Current ophthalmic antibiotics have inherent strengths and weaknesses.
- Advancements in fluoroquinolones provide clinicians with more potent antimicrobial options.
- Future ophthalmic antibiotic development will likely leverage quorum sensing and genomics for improved efficacy and safety.